What is Deciphex?
Headquartered in Ireland, Deciphex is a pioneering software enterprise dedicated to the digital transformation of pathology. By leveraging advanced artificial intelligence, the company provides sophisticated tools designed to enhance the efficiency and accuracy of diagnostic processes. Its platform is engineered to solve the most pressing challenges in modern pathology, offering a robust solution for clinical and research environments that require high-throughput, reliable diagnostic capabilities. Through its cleverly positioned technology, Deciphex is effectively bridging the gap between traditional pathology practices and the future of automated, data-driven healthcare.
How much funding has Deciphex raised?
Deciphex has raised a total of $67.1M across 6 funding rounds:
Other Financing Round
$2.3M
Series A
$6.2M
Series B
$11.5M
Other Financing Round
$4.2M
Debt
$10.6M
Series C
$32.3M
Other Financing Round (2019): $2.3M, investors not publicly disclosed
Series A (2020): $6.2M led by Act Venture Capital Ltd, Halo Business Angel Network, NextSteps Capital LLC, GI Partners of Illinois LLC, Enterprise Ireland, and Irrus Investments
Series B (2022): $11.5M supported by Charles River Laboratories India Private and Act Venture Capital
Other Financing Round (2023): $4.2M featuring Seroba Life Sciences Management
Debt (2023): $10.6M backed by Claret Capital Partners
Series C (2025): $32.3M with participation from Seroba, NextSteps Capital, Molten Ventures, ACT Venture Capital, Irrus Investments, hban.cn, and Charles River
Key Investors in Deciphex
Seroba
A European life sciences venture capital firm based in Dublin and Paris, specializing in backing cutting-edge biotech and medtech innovation to transform unmet medical needs.
Molten Ventures
One of Europe's most active venture capital firms, providing patient capital and international network access to high-growth, disruptive technology companies.
ACT Venture Capital
An Irish-based venture capital firm with over 15 years of experience, focused on partnering with innovative teams to build market-leading companies with significant long-term value.
What's next for Deciphex?
With this latest capital injection, Deciphex is well-positioned to accelerate its international expansion and deepen its investment in R&D. The company's strategic roadmap focuses on scaling its AI-powered diagnostic suite to meet the increasing global demand for digital pathology services. By continuing to foster partnerships with major industry stakeholders and research institutions, Deciphex aims to solidify its market presence and drive the next wave of innovation in medical diagnostics, ultimately setting a new standard for efficiency in clinical pathology workflows.
See full Deciphex company page
